SinoMab BioScience (3681.HK) Osake Kurssi

SinoMab BioScience Ltd is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of SinoMab BioScience Ltd in the market include companies such as Johnson & Johnson, Roche Holding AG, Pfizer Inc., and Novartis AG.

SinoMab BioScience Ltd is a leading biotechnology company specializing in antibody research and development. Established in 2001, the company has rapidly grown to become a renowned player in the pharmaceutical industry. With its headquarters in Hong Kong, SinoMab has successfully expanded its operations worldwide, focusing on the discovery and production of innovative monoclonal antibodies for therapeutic treatments. By leveraging cutting-edge technologies and strategic partnerships, SinoMab has built a robust pipeline of potential drugs, targeting various diseases including cancer, inflammation, and autoimmune disorders. With a strong commitment to delivering high-quality and effective treatment options, SinoMab BioScience Ltd continues to make significant contributions to the field of biomedicine.

SinoMab BioScience Ltd has achieved several significant milestones in its journey. Firstly, the company successfully developed and commercialized multiple monoclonal antibody drugs, leading to notable advancements in the field of targeted therapeutics. Additionally, SinoMab BioScience Ltd has forged strategic partnerships with renowned pharmaceutical companies, expanding its global presence and fostering collaboration for further growth. The company's dedication to research and innovation has resulted in the successful development of novel antibody therapeutics, addressing critical unmet medical needs. SinoMab BioScience Ltd's relentless pursuit of excellence has earned it a reputation as a leader in the biopharmaceutical industry, with its groundbreaking discoveries and commitment to improving patient outcomes.

SinoMab BioScience Ltd is primarily present in Hong Kong and Mainland China.

SinoMab BioScience Ltd represents a strong commitment to delivering innovative biopharmaceutical solutions. The company values scientific excellence, dedication to patients, and respect for employees. With a mission to improve global health, SinoMab is driven by a corporate philosophy of integrity and collaboration. By leveraging cutting-edge research and development capabilities, SinoMab strives to discover breakthrough therapies for unmet medical needs. With a focus on quality and safety, SinoMab BioScience Ltd aims to create value for patients, shareholders, and the healthcare community.

Nykyisellä valuuttakurssilla SinoMab BioScience-osake noteerataan hintaan 0,12 EUR (0,86 CNY).

SinoMab BioScience Ltd is a biopharmaceutical company based in Hong Kong. The company aims to develop innovative therapies and therapeutics to meet the needs of patients worldwide. SinoMab BioScience operates an integrated business model consisting of three sectors: research and development, manufacturing, and distribution of biopharmaceutical products. The company conducts intensive research and development to bring novel therapies and drugs to the market. They strive to find groundbreaking technologies and therapeutic solutions to fulfill unmet patient needs. SinoMab BioScience produces its biopharmaceutical products in accordance with international Good Manufacturing Practice (GMP) standards to ensure high product quality. The company distributes its products in China and international markets, with strategic partnership support for marketing. Currently, SinoMab BioScience offers four main products, including IBI303, IBI301, SMC-110101, and Leukotuximab, which are used for the treatment of various conditions such as lung cancer, solid tumors, macular degeneration, and acute lymphoblastic leukemia. In summary, SinoMab BioScience operates an integrated business model and offers innovative biopharmaceutical products, aiming to fulfill unmet patient needs through intensive research and development. Through strategic partnerships and international presence, the company is able to distribute its products worldwide, making a positive impact on global patient health.

odotettu liikevaihto SinoMab BioScience on 7,82 M CNY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto SinoMab BioScience on −199,54 M CNY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

SinoMab BioScience:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,92. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan SinoMab BioScience-osakkeen arvostusta.

SinoMab BioScience:n hinta-myynti-suhde (P/S) on tällä hetkellä 151,14. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii SinoMab BioScience-osakkeen arvostuskennuslukuna.

SinoMab BioScience:n Eulpool-laatuscore on 3/10.

SinoMab BioScience:n ISIN on HK0000544194. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

SinoMab BioScience:n ticker on 3681.HK. Tämä pörssinoteeraus käytetään SinoMab BioScience-osakkeiden kauppaan pörssissä.